Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12receptorsin vitro

Pharmacodynamic effects during the transition between cangrelor and prasugrel

(2015) David J. Schneider et al.   CORONARY ARTERY DISEASE

Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: A meta-analysis of randomized trials

(2014) Xiao-Fang Tang et al.   ATHEROSCLEROSIS

Pharmacodynamic Effects During the Transition Between Cangrelor and Ticagrelor

(2014) David J. Schneider et al.   JACC-Cardiovascular Interventions

Comparison of Prasugrel and Ticagrelor Loading Doses in ST-Segment Elevation Myocardial Infarction Patients

(2013) Guido Parodi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events

(2013) Deepak L. Bhatt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment–Elevation Myocardial Infarction

(2012) Dimitrios Alexopoulos et al.   Circulation-Cardiovascular Interventions

Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery

(2012) Dominick J. Angiolillo et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials

(2012) Dominick J. Angiolillo et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease

(2009) Paul A. Gurbel et al.   CIRCULATION

P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use

(2009) L. Wallentin   EUROPEAN HEART JOURNAL

Pharmacokinetics and Pharmacodynamics of a Bolus and Infusion of Cangrelor: A Direct, Parenteral P2Y12 Receptor Antagonist

(2009) Wendell S. Akers et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The reversible P2Y12antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function

(2008) N. L. DOVLATOVA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The active metabolite of prasugrel effectively blocks the platelet P2Y12receptor and inhibits procoagulant and pro-inflammatory platelet responses

(2008) Heather M. Judge et al.   PLATELETS

Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect

(2007) Steven R. Steinhubl et al.   THROMBOSIS RESEARCH